Marcus Schindler, Novo Nordisk CSO (Ryan Cross for Endpoints News)
February 28, 2024 04:15 PM ESTUpdated February 29, 08:48 AM
R&D
Pharma

No­vo Nordisk plans for life af­ter We­govy, set­ting up roots in Boston to try and find its fu­ture

Ryan Cross

Senior Science Correspondent

LEX­ING­TON, Mass. — The world’s sec­ond-most valu­able phar­ma com­pa­ny is on the hunt for its next big break­through, and it thinks the se­quel to Ozem­pic or …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times